5 Results

People

  1. Oxnard
    Oxnard
  2. Kris
    Kris
  3. Miller
    Miller
  4. Pao
    Pao
  5. Riely
    Riely
  6. Sima
    Sima
  7. Ladanyi
    Ladanyi
  8. Arcila
    Arcila
  9. Azzoli
    Azzoli
  10. Chaft
    Chaft

Groups

  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (4)
  4. GSK Faculty (3)
  5. Human Oncology and Pathogenesis Program (3)
  6. Tow Center for Developmental Oncology (TCDO) (3)
  7. Biostatistics Service (1)
  8. Body Imaging Service (1)
  9. Epidemiology and Biostatistics (1)
  10. Gastrointestinal Oncology Service (1)
  1. "gefitinib"
  2. "Geoffrey Oxnard"
Formats
  1. Journal Article (5)
Groups
  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (4)
  4. GSK Faculty (3)
  5. Human Oncology and Pathogenesis Program (3)
  6. Tow Center for Developmental Oncology (TCDO) (3)

More Groups

People
  1. Geoffrey Oxnard (5)
  2. Mark Kris (4)
  3. Vincent Miller (4)
  4. Camelia Sima (3)
  5. Gregory Riely (3)
  6. Marc Ladanyi (3)

More People

Years
  1. 2011 (3)
  2. 2010 (2)
Publications
  1. Clinical Cancer Research (4)
  2. Oncology (Norwalk) (1)
Publishers
  1. American Association for Cancer Research (4)
  2. C M P Medica LLC * The Oncology Group (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
    Journal Article

    Chaft, J. E.; Oxnard, G. R.; Sima, C. S.; Kris, M. G.; Miller, V. A.; Riely, G. J.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
    Journal Article

    Oxnard, G. R.; Arcila, M. E.; Sima, C. S.; Riely, G. J.; Chmielecki, J.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
    Journal Article

    Zhao, B.; Oxnard, G. R.; Moskowitz, C. S.; Kris, M. G.; Pao, W.; Guo, P.; Rusch, V.; Ladanyi, M.; Rizvi, N. A.; Schwartz, L. H.
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
    Journal Article

    Oxnard, G. R.; Miller, V. A.
    Oncology (Norwalk) (2010)

    Fulltext@MSK | Save